Abstract
A M-BACOD regimen using an increased dose of Adriyamycin has been administered to 18 patients with non-Hodgkin's lymphoma. Sixty-three percent of the patients who had been previously untreated obtained a complete remission and the 2-year survival rate of those who evidenced a complete response reached 71%. The stage of the lymphoma was found to be a prognostic factor for a complete remission, while LDH and tumor response had an influence upon survival.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Dexamethasone / administration & dosage
-
Doxorubicin / administration & dosage
-
Drug Evaluation
-
Female
-
Humans
-
L-Lactate Dehydrogenase / blood
-
Leucovorin / administration & dosage
-
Logistic Models
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / mortality
-
Lymphoma, Non-Hodgkin / pathology
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Multivariate Analysis
-
Neoplasm Staging
-
Prognosis
-
Remission Induction
-
Survival Rate
-
Vincristine / administration & dosage
Substances
-
Bleomycin
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
L-Lactate Dehydrogenase
-
Leucovorin
-
Methotrexate